Jon K. Obst
Vancouver, BC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Drugging the intrinsically disordered transactivation domain of androgen receptor.
Journal: Signal transduction and targeted therapy
Published: October 07, 2025
Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer.
Journal: Steroids
Published: May 10, 2024
Rational optimization of a transcription factor activation domain inhibitor.
Journal: Nature structural & molecular biology
Published: November 21, 2022
Ralaniten Sensitizes Enzalutamide-Resistant Prostate Cancer to Ionizing Radiation in Prostate Cancer Cells that Express Androgen Receptor Splice Variants.
Journal: Cancers
Published: June 17, 2020
Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies.
Journal: ACS pharmacology & translational science
Published: August 20, 2019
Directing abiraterone metabolism: balancing the scales between clinical relevance and experimental observation.
Journal: Translational cancer research
Published: September 01, 2016
Conditional protein splicing of α-sarcin in live cells.
Journal: Molecular bioSystems
Published: February 01, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026